Announcements
- Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
- Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Life Science Cares Launches in Switzerland
- Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
- Molecular Partners Announces Dismissal of Class Action Lawsuit
- Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
More ▼
Key statistics
On Wednesday, Molecular Partners AG (MOLN:NSQ) closed at 3.80, 14.46% above the 52 week low of 3.32 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.63 |
---|---|
High | 3.80 |
Low | 3.63 |
Bid | 1.84 |
Offer | 3.82 |
Previous close | 3.58 |
Average volume | 1.58k |
---|---|
Shares outstanding | 36.68m |
Free float | 33.17m |
P/E (TTM) | -- |
Market cap | 136.79m USD |
EPS (TTM) | -1.95 USD |
Data delayed at least 15 minutes, as of May 22 2024 18:23 BST.
More ▼